Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03391726

CART-19 Cells for R/R B-cell Lymphoma — CCFRRBL  

Relapsed or Refractory B-cell Lymphoma Clinical Trial

Official title:
CART-19 Cells For Patients With Relapsed or Refractory B-cell Lymphoma

Clinical Trial Summary

Relapsed/Refractory B Cell Lymphoma is a challenge to be treated, however,CART-19 cells could be very promosing. This study aims to assess the safety and toxicity of CART-19 cells for patients with relapse or refractory B cell lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03391726
Study type Interventional
Source Fujian Medical University
Contact Jianda Hu, Prof.M.D.Ph.D
Phone 86-13959169016
Email drjiandahu@163.com
Status Recruiting
Phase Phase 2/Phase 3
Start date January 1, 2016
Completion date December 2020
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04056975 - Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma Phase 1
Not yet recruiting NCT06062641 - Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL Phase 2
Recruiting NCT05806580 - Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma Phase 4
Recruiting NCT03208556 - Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma Phase 1
Not yet recruiting NCT05814848 - A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma Phase 4
Recruiting NCT04887025 - Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma Phase 1
Recruiting NCT05720052 - A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma Phase 1/Phase 2
Recruiting NCT06045585 - JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma Early Phase 1